Investigation of ICAM-1 and B3 integrin gene variations and ICAM-1 serum levels in patients with non-small cell lung cancer

Lung cancer is widespread cancer in the worldwide. Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancers. ICAM-1 and β3 integrin , have been studied in various cancer types due the fact that they play essential role in the angiogenesis, tumor growth and metastasis. Our principal purpose in this study is to explore gene polymorphisms in ICAM-1 and β3 integrin molecular pathway in NSCLC patients and to clarify whether these values are effective on the etiopathogenesis and prognosis of the disease. ICAM-1 and β3 integrin gene polymorphisms were determined by using PCR-RFLP techniques. Also serum ICAM levels were determined by ELISA method. There was no statistically significant difference between patient with NSCLC and healthy control groups with regard to β3 Integrin Leu33Pro gene polymorphism. However, in patients with NSCLC, AG genotype frequency and G allele carriers of ICAM K469E variant were found to be higher than the control group and the difference was statistically significant. It has been determined that having a G allele increased approximately 2,95 fold the risk of disease and also carrying of AGTC combined genotype increased approximately 2,509 fold the risk of disease. When patients were evaluated according to tumor stage, serum levels of ICAM-1 gene in early tumor stage was found to be significantly higher than in advanced tumor stage (p=0,013). No significant difference was determined between the range of pathology findings and serum ICAM levels (p>0,05).